.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH51_SitagliptinAndSimvastati.SitagliptinAndSimvastati .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH51_SitagliptinAndSimvastati.SitagliptinAndSimvastati| name: | SitagliptinAndSimvastatin |
| ATC code: | A10BH51 | route: | oral |
| n-compartments | 1 |
Sitagliptin and simvastatin is a fixed-dose combination drug approved for use in the management of type 2 diabetes mellitus and dyslipidemia. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control, while simvastatin is a HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk. This combination allows for convenient co-administration to patients requiring both glycemic and cholesterol management.
No published population pharmacokinetic parameters are available specifically for the fixed-dose combination of sitagliptin and simvastatin (ATC A10BH51). Below are estimated parameters based on available data for the individual monotherapies in healthy adults receiving typical oral doses.